The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.
Can you spend some uninterrupted time looking at one piece of art? We’ll bring you a new one on the first Monday of each month. Sign up for a monthly email notification. Can you spend some ...
Football notes: With a 6-1 record, Costa Mesa is off to its best start since ...
November 2, 2025 • NPR's Ayesha Rascoe plays the puzzle with WNIJ listener Scott Anderson of Beloit, Wisconsin, along with Weekend Edition Puzzlemaster Will Shortz.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback